The proposed bill, known as "The Prescription Drug Sales Representative Disclosure Act," aims to regulate the activities of pharmaceutical sales representatives. It requires prescription drug manufacturers to provide the Department of Business Regulation with a detailed and updated list of each pharmaceutical sales representative engaged by the manufacturer who markets prescription drugs to healthcare providers in the state. Manufacturers must also pay an annual fee of $55 for each representative listed. Any changes to the list must be reported to the department within 60 days, and failure to comply may result in civil penalties of up to $10,000 per violation.

Additionally, the act mandates that each pharmaceutical sales representative submit an annual report detailing any compensation, gifts, or things of value provided to healthcare providers, with specific thresholds for reporting. The report must include a list of providers who received items exceeding $100 in value or total compensation exceeding $250 in the aggregate, as well as the name and manufacturer of each prescription drug for which free samples were provided.

The Department of Business Regulation is tasked with analyzing the submitted information and compiling an annual report on the activities of pharmaceutical sales representatives in the state. This report will be posted on the department's website and submitted to the governor, the director of the Department of Health, the commissioner of the Office of Health Insurance, and the leadership of the General Assembly.

The act is set to take effect on January 1, 2026.